PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1159447
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1159447
Influenza Vaccine Market Forecasts to 2028 - Global Analysis By Vaccine Type, Type, Technology, Age Group, Route of Administration, Distribution Channel and By Geography
According to Stratistics MRC, the Global Influenza Vaccine Market is accounted for $8.11 billion in 2022 and is expected to reach $19.34 billion by 2028 growing at a CAGR of 15.58% during the forecast period. The influenza virus is what causes the contagious respiratory ailment known as influenza. Fever, coughing, soreness in the muscles and joints, headaches, and extreme exhaustion are all symptoms of influenza. Flu-related illness can range from mild to severe, and it can occasionally be fatal. For the purpose of preventing influenza infections, vaccinations are advised. The urgent need for an effective influenza vaccine is being driven by the swift global spread of influenza virus epidemics. The main driver fueling the market's expansion throughout the projection period is a strong product pipeline.
According to the Centers for Disease Control and Prevention in 2020, flu resulted in 9 million and 41 million illnesses with 140,000 to 710,000 hospitalizations. According to the World Health Organization (WHO), 2018, influenza cases related hospitalization ranges in 3-5 million cases for severe illness, whereas deaths related to influenza are about 290,000 to 650,000.
Market Dynamics:
Driver:
Rise with increasing government support for immunization
Government support and surveillance of influenza vaccination are increasing, which is driving the market expansion for influenza vaccines globally. The administration, distribution, and supply of influenza vaccines must be monitored on both a global and national scale through surveillance. However, a number of nations have various labelling standards along with lengthy deadlines. This makes the procedure of carrying out clinical trials on a worldwide scale even more complicated.
Restraint:
Difficulty in diagnosis
Because influenza's most obvious symptoms, such as aches, coughs, and fevers, are similar to many other common illnesses, diagnosing influenza can be challenging. There are numerous methods for figuring out whether a patient is infected with the flu or not. However, most patients do not seek an influenza diagnosis. The likelihood of false positive or false negative test results has an impact on the adoption rate. Although there are sophisticated diagnostic methods for the precise detection of influenza infection, the time it takes to receive the results of those tests can be several days. This delays diagnosis and eventually lowers the demand for the medication. All of these elements could limit the market's expansion for flu vaccines during the anticipated period.
Opportunity:
The need for revaccination
The patient may need to be hospitalised with the potentially lethal illness of influenza. The best method of preventing influenza is vaccination because prevention is always preferable to treatment. To ensure optimal protection, vaccinations should be administered yearly prior to the start of flu season. Due to the antigenic drift of influenza viruses with time and the waning of vaccine-specific antibodies, this repeated dose is necessary. Additionally, the CDC advises getting the seasonal flu shot every year as the most effective strategy to lower your chance of contracting the illness. Therefore, revaccination aids in boosting vaccine sales which drives influenza vaccine market growth.
Threat:
Manufacturing delays
The market for influenza vaccinations is a difficult one for a number of reasons. Seasonal influenza vaccines need to be developed and delivered in a short period of time-six months-in addition to requiring yearly upgrades. Losses of revenue and market share may be the result of manufacturing delays and decreased output. In addition, the demand for seasonal influenza vaccines varies and is frequently unpredictable due to variables including the weather, the timing and length of the influenza season, the availability of the vaccine, and vaccination knowledge among the general public. Planning for manufacturing is challenging due to these issues. Even more unpredictably, the pandemic influenza vaccine industry relies nearly entirely on government stockpiles and supply agreements.
COVID-19 Impact
The coronavirus pandemic has an impact on the global routine immunisation programmes and campaigns run in developed and poor nations. However, during the pandemic, vaccination rates rose as a result of a number of factors, including pressure from health departments and the expansion of government programmes offering free flu shots. Another factor influencing the uptake of flu vaccines is the public's rising knowledge of the increased risk of contracting COVID19 if the flu weakens the immune system.
The inactivated segment is expected to be the largest during the forecast period
The inactivated segment is estimated to have a lucrative growth, due to the fact that inactivated vaccines are standardised based on the particular virus strain, there is an increase in demand for them in both developing and developed nations. This feature of the vaccines aids in reducing the flu in a shorter amount of time and reversing any beneficial effects. The rising demand and increased influenza prevalence are to
The hospital & retail pharmacies segment is expected to have the highest CAGR during the forecast period
The hospital & retail pharmacies segment is anticipated to witness the fastest CAGR growth during the forecast period, due to vaccination being commonly favoured and being done at smaller institutions, this leading position has developed. In the coming years, a high market value is anticipated in part due to the hospitals' enormous supply of vaccines.
Region with highest share:
North America is projected to hold the largest market share during the forecast period owing to the presence of major players in the area is responsible for the region's dominance in the market. Additionally, improvements in vaccine delivery, a greater focus on immunisation programmes by the government, the creation of innovative vaccines, and an increase in seasonal influenza prevalence are all key revenue-generators in the influenza vaccine industry.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to rapid economic development, rising disposable income, government initiatives, and rising seasonal influenza incidence are some key factors that are likely to fuel revenue generation opportunities in the market. Government concentration is also increasing in Asian countries to improve healthcare facilities.
Key players in the market
Some of the key players profiled in the Influenza Vaccine Market include Csl Limited (Seqirus GmbH), Emergent Biosolutions, Astrazeneca Plc (Astrazeneca), Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Biodiem, Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Sanofi, Sinovac Biotech Ltd., Novartis Ag, Pfizer, Inc., Gamma Vaccines Pty Ltd., Seqirus, Moderna TX, Abbott.
Key Developments:
In March 2022, Seqirus announced the approval of Flucelvax quadrivalent, a cell based influenza vaccine for individuals in the age group of two years and older. This approval by Health Canada made children in the age group of 2 to 18 years eligible for these vaccines.
In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company, for the development of new and seasonal vaccines for influenza.
In February 2021, GlaxoSmithKline plc expanded a pre-existing collaboration with Vir Biotechnology with an aim to develop monoclonal antibodies for the prevention and treatment of influenza.
In January 2021, ModernaTX, Inc. announced that the company has planned to utilize mRNA technology to develop and manufacture influenza, HIV, and Nipah virus vaccines.
In February 2020, BioDiem announced the approval of Changchun BCHT Biotechnology Co (BCHT)'s LAIV vaccine by the Chinese National Medical Products Administration (NMPA).
In February 2020, Abbott launched a new inactivated quadrivalent vaccine for use in children below three years of age. This new launch expanded the company's established pharmaceutical portfolio and the spread of flu vaccines to a critical market such as India.
Vaccine Types Covered:
- Trivalent
- Quadrivalent
Types Covered:
- Pandemic
- Seasonal
- Inactivated
- Live Attenuated
- Other Types
Technologies Covered:
- Egg-Based
- Cell-Based
Age Groups Covered:
- Pediatric
- Adult
Route of Administrations Covered:
- Injection
- Nasal Spray
Distribution Channels Covered:
- Hospital & Retail Pharmacies
- Government Suppliers
- Other Distribution Channels
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Technology Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Influenza Vaccine Market, By Vaccine Type
- 5.1 Introduction
- 5.2 Trivalent
- 5.3 Quadrivalent
6 Global Influenza Vaccine Market, By Type
- 6.1 Introduction
- 6.2 Pandemic
- 6.3 Seasonal
- 6.4 Inactivated
- 6.5 Live Attenuated
- 6.6 Other Types
7 Global Influenza Vaccine Market, By Technology
- 7.1 Introduction
- 7.2 Egg-Based
- 7.3 Cell-Based
8 Global Influenza Vaccine Market, By Age Group
- 8.1 Introduction
- 8.2 Pediatric
- 8.3 Adult
9 Global Influenza Vaccine Market, By Route of Administration
- 9.1 Introduction
- 9.2 Injection
- 9.3 Nasal Spray
10 Global Influenza Vaccine Market, By Distribution Channel
- 10.1 Introduction
- 10.2 Hospital & Retail Pharmacies
- 10.3 Government Suppliers
- 10.4 Other Distribution Channels
11 Global Influenza Vaccine Market, By Geography
- 11.1 Introduction
- 11.2 North America
- 11.2.1 US
- 11.2.2 Canada
- 11.2.3 Mexico
- 11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 Italy
- 11.3.4 France
- 11.3.5 Spain
- 11.3.6 Rest of Europe
- 11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 New Zealand
- 11.4.6 South Korea
- 11.4.7 Rest of Asia Pacific
- 11.5 South America
- 11.5.1 Argentina
- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
- 11.6 Middle East & Africa
- 11.6.1 Saudi Arabia
- 11.6.2 UAE
- 11.6.3 Qatar
- 11.6.4 South Africa
- 11.6.5 Rest of Middle East & Africa
12 Key Developments
- 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 12.2 Acquisitions & Mergers
- 12.3 New Product Launch
- 12.4 Expansions
- 12.5 Other Key Strategies
13 Company Profiling
- 13.1 Csl Limited (Seqirus GmbH)
- 13.2 Emergent Biosolutions
- 13.3 Astrazeneca Plc (Astrazeneca)
- 13.4 Glaxosmithkline Plc
- 13.5 F. Hoffmann-La Roche Ltd.
- 13.6 Biodiem
- 13.7 Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
- 13.8 Sanofi
- 13.9 Sinovac Biotech Ltd.
- 13.10 Novartis Ag
- 13.11 Pfizer, Inc.
- 13.12 Gamma Vaccines Pty Ltd.
- 13.13 Seqirus
- 13.14 Moderna TX
- 13.15 Abbott
List of Tables
- Table 1 Global Influenza Vaccine Market Outlook, By Region (2020-2028) ($MN)
- Table 2 Global Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
- Table 3 Global Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
- Table 4 Global Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 5 Global Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 6 Global Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
- Table 7 Global Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
- Table 8 Global Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
- Table 9 Global Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
- Table 10 Global Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 11 Global Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
- Table 12 Global Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
- Table 13 Global Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
- Table 14 Global Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 15 Global Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 16 Global Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 17 Global Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 18 Global Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
- Table 19 Global Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
- Table 20 Global Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 21 Global Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
- Table 22 Global Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
- Table 23 Global Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
- Table 24 North America Influenza Vaccine Market Outlook, By Country (2020-2028) ($MN)
- Table 25 North America Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
- Table 26 North America Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
- Table 27 North America Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 28 North America Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 29 North America Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
- Table 30 North America Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
- Table 31 North America Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
- Table 32 North America Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
- Table 33 North America Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 34 North America Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
- Table 35 North America Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
- Table 36 North America Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
- Table 37 North America Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 38 North America Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 39 North America Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 40 North America Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 41 North America Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
- Table 42 North America Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
- Table 43 North America Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 44 North America Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
- Table 45 North America Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
- Table 46 North America Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
- Table 47 Europe Influenza Vaccine Market Outlook, By Country (2020-2028) ($MN)
- Table 48 Europe Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
- Table 49 Europe Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
- Table 50 Europe Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 51 Europe Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 52 Europe Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
- Table 53 Europe Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
- Table 54 Europe Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
- Table 55 Europe Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
- Table 56 Europe Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 57 Europe Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
- Table 58 Europe Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
- Table 59 Europe Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
- Table 60 Europe Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 61 Europe Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 62 Europe Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 63 Europe Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 64 Europe Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
- Table 65 Europe Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
- Table 66 Europe Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 67 Europe Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
- Table 68 Europe Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
- Table 69 Europe Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
- Table 70 Asia Pacific Influenza Vaccine Market Outlook, By Country (2020-2028) ($MN)
- Table 71 Asia Pacific Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
- Table 72 Asia Pacific Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
- Table 73 Asia Pacific Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 74 Asia Pacific Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 75 Asia Pacific Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
- Table 76 Asia Pacific Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
- Table 77 Asia Pacific Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
- Table 78 Asia Pacific Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
- Table 79 Asia Pacific Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 80 Asia Pacific Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
- Table 81 Asia Pacific Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
- Table 82 Asia Pacific Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
- Table 83 Asia Pacific Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 84 Asia Pacific Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 85 Asia Pacific Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 86 Asia Pacific Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 87 Asia Pacific Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
- Table 88 Asia Pacific Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
- Table 89 Asia Pacific Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 90 Asia Pacific Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
- Table 91 Asia Pacific Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
- Table 92 Asia Pacific Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
- Table 93 South America Influenza Vaccine Market Outlook, By Country (2020-2028) ($MN)
- Table 94 South America Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
- Table 95 South America Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
- Table 96 South America Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 97 South America Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 98 South America Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
- Table 99 South America Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
- Table 100 South America Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
- Table 101 South America Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
- Table 102 South America Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 103 South America Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
- Table 104 South America Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
- Table 105 South America Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
- Table 106 South America Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 107 South America Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 108 South America Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 109 South America Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 110 South America Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
- Table 111 South America Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
- Table 112 South America Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 113 South America Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
- Table 114 South America Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
- Table 115 South America Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
- Table 116 Middle East & Africa Influenza Vaccine Market Outlook, By Country (2020-2028) ($MN)
- Table 117 Middle East & Africa Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
- Table 118 Middle East & Africa Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
- Table 119 Middle East & Africa Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
- Table 120 Middle East & Africa Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
- Table 121 Middle East & Africa Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
- Table 122 Middle East & Africa Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
- Table 123 Middle East & Africa Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
- Table 124 Middle East & Africa Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
- Table 125 Middle East & Africa Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
- Table 126 Middle East & Africa Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
- Table 127 Middle East & Africa Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
- Table 128 Middle East & Africa Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
- Table 129 Middle East & Africa Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
- Table 130 Middle East & Africa Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 131 Middle East & Africa Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
- Table 132 Middle East & Africa Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
- Table 133 Middle East & Africa Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
- Table 134 Middle East & Africa Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
- Table 135 Middle East & Africa Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
- Table 136 Middle East & Africa Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
- Table 137 Middle East & Africa Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
- Table 138 Middle East & Africa Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
